3,837 IQVIA Holdings Inc. $IQV Shares Sold by SFE Investment Counsel

SFE Investment Counsel reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 55,206 shares of the medical research company’s stock after selling 3,837 shares during the period. IQVIA comprises approximately 2.1% of SFE Investment Counsel’s holdings, making the stock its 10th largest position. SFE Investment Counsel’s holdings in IQVIA were worth $14,842,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in IQVIA during the 2nd quarter valued at $2,811,292,000. Dimensional Fund Advisors LP raised its stake in shares of IQVIA by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after purchasing an additional 66,643 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of IQVIA during the second quarter valued at $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of IQVIA by 8.3% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company’s stock valued at $209,057,000 after buying an additional 93,779 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $266.93 on Friday. The firm’s 50 day moving average price is $266.22 and its 200-day moving average price is $210.41. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $284.50. The company has a quick ratio of 0.71, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $43.99 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the previous year, the business posted $3.00 earnings per share. Equities research analysts expect that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IQV shares. Robert W. Baird boosted their price objective on shares of IQVIA from $324.00 to $328.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings cut shares of IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $295.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Mizuho increased their price target on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.

Insider Buying and Selling at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.